STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that emerged in a promising research field. One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy. Researchers determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell therapy, ...